On June 23, 2022, Iroquois Capital Management, LLC announced that it has nominated a slate of 7 director candidates, Richard Abbe, Stephen Friscia, Charles S. Ryan, Jonathan L. Schechter, Joshua N. Silverman, Kimberly Page, and Jude C. Uzonwanne, for election to PharmaCyte Biotech, Inc.'s Board of Directors at the Company's upcoming 2022 annual meeting of stockholders. Iroquois Capital also announced that it has publicly delivered a letter to the Company's stockholders making clear the case for a reconstitution of the Board with professionals possessing the requisite skillsets, experience, drive and sense of accountability needed to turn the Company around.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | +7.43% | +10.71% | +0.46% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.46% | 17.08M | |
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Iroquois Capital Management Nominates Candidates to the Board of PharmaCyte Biotech